Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neiromidin for lumbosacral radiculopathy
2019-002632-90Phase 3Completed
- Sponsor
- "Olainfarm" AS
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lumbosacral radiculopathy comparing Neiromidin 20 mg with Placebo (2 arms). Primary endpoint: Change in Oswestry Disability Index (ODI). Started Jul 2020; status: completed.
02
Drugs
Ipidacrine
03
Conditions
lumbosacral radiculopathy
Beyond the preview
Go deeper on 2019-002632-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002632-90.